State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator (<i>CFTR</i>) Modulators and Triple-Combination Therapy

State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator (<i>CFTR</i>) Modulators and Triple-Combination Therapy

Cystic fibrosis (CF) is the most common life-limiting inherited disease in Caucasian populations, affecting approximately 80,000 people worldwide. CF is a complex multi-organ monogenic autosomal recessive disorder caused by a mutation in cystic fibrosis transmembrane conductance regulator (<i>...

Full description

Bibliographic Details
Main Authors: Aniello Meoli, Valentina Fainardi, Michela Deolmi, Giulia Chiopris, Francesca Marinelli, Caterina Caminiti, Susanna Esposito, Giovanna Pisi
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Pharmaceuticals
Subjects:
<i>CFTR</i>
<i>CFTR</i> modulator
cystic fibrosis
F508del
ivacaftor
Online Access:https://www.mdpi.com/1424-8247/14/9/928

Internet

https://www.mdpi.com/1424-8247/14/9/928

Similar Items